PAX5 and acute lymphoblastic leukemia: 58.3% in CML/BCL and PAX5 loss is seen in 51.% of Ph(+)ALL vs. 58.3% in CML/BCL, while deletions of IKZNF1 are seen in 20 of 22 adults with Ph(+)ALL (90.9%) [14] and our aCGH analysis at 1 K resolution detected loss in 10/12 CML/BCL samples (83.3%).